United States: FTC Submits Amicus In Mylan v. Celgene, Citing Potential Refusal To Deal Concerns

Last Updated: September 16 2014
Article by Jonathan H. Hatch and Thomas W. Pippert

The FTC has submitted an amicus brief in Mylan Pharmaceuticals Inc. v. Celgene Corp., 2:14-CV-2094 (D.N.J.), offering support in favor of Mylan's claims. Mylan sued Celgene in April 2014, bringing claims related to its attempts to develop generic versions of Revlimid and Thalomid, brand drugs used to treat certain forms of cancer. Due to safety concerns, the FDA required Celgene to adopt Risk Evaluation and Mitigation Strategies ("REMS") that limit their distribution. As a result, Mylan claims that it cannot purchase any of the drugs through distributors, and that Celgene has refused to sell any amounts of the drugs directly. Without samples, Mylan cannot perform the bioequivalence testing necessary for Abbreviated New Drug Applications. Mylan alleges that Celgene's use of REMS to deny it access to the drugs is pretextual, and are designed to prevent any generic entrants. Mylan's complaint contains claims for violation of Section 2 of the Sherman Act by Celgene under monopolization and refusal to deal theories, Section 1 of the Sherman Act and Sections 15 and 26 of the Clayton Act for conspiracy between Celgene and its distributors in restraint of trade, and violations of the New Jersey Antitrust Act. Celgene has moved to dismiss.

The FTC, arguing that it has an interest in disputes which concern restrictions on the entry of generic drugs into the market, argues that the antitrust laws are applicable to the dispute. While recognizing that one of the purposes of the Hatch-Waxman Act is to maintain incentives for innovation, it also argues another purpose is to promote generic competition and that "[d]istribution restrictions associated with a REMS can, in fact, raise serious competitive concerns."

With respect to the Section 2 claims, the FTC argues that Mylan's theory fits within the Supreme Court's decision in Aspen Skiing Co. v. Aspen Highlands Skiing Corp., 472 U.S. 585 (1985) and Otter Tail Power Co. v. United States, 410 U.S. 366 (1973), arguing that Celgene's refusal to sell samples of its product to Mylan deprives it of an essential service or product, like Otter Tail's refusal to allow other towns to use its power transmission network or Aspen Skiing Co's refusal to participate in a joint lift ticket (or sell its own tickets to Highlands at retail price). The FTC argues that under this precedent, a refusal to deal can be inappropriate where it impairs the opportunities of rivals or does not further competition on the merits.

Although the FTC acknowledges that the Supreme Court's more recent decision in Verizon Commc'ns Inc. v. Law Offices of Curtis V. Trinko, LLP, 540 U.S. 398 (2004) reaffirmed that a monopolist is ordinarily free to refuse to deal with a rival, it argues that Mylan's claims are distinguishable from those in Trinko. First, contrary to the way some lower courts have interpreted Trinko, the FTC argues that no prior course of dealing is required to state a refusal to deal claim. Although the FTC acknowledges that a prior course of dealing may be useful for demonstrating that the alleged monopolist is foregoing an otherwise profitable transaction, it is not required, and that the key to a refusal to deal claim is a willingness by the alleged monopolist to sacrifice short term profits in order to maintain a favorable market position in the long term. (The FTC notes that Mylan has alleged that it is willing to pay full retail price for the drugs samples it wants, which it argues supports an inference that the sales would be profitable to Celgene.) Second, the FTC argues that unlike Trinko (where Verizon refused to provide access to a new produce it was required to develop), here Celgene is already in the business of selling the drugs, and that in addition to distributors was also willing to sell the drugs to non-competitor research organizations. The FTC argues that refusal to engage in similar conduct with a competitor can support a viable antitrust theory. Third, the FTC argues that requiring a sale under these circumstances will not undermine brand manufacturers incentives to innovate, as it will merely mirror the general Hatch-Waxman framework that exists for drugs that are not subject to REMS, and that brand manufacturers will remain free to exercise their patent rights. The FTC also argues that FDA requirements like REMS should not be used to undermine the Hatch-Waxman Act by limiting legitimate competition from generics.

With regard to the Section 1 arguments, the FTC briefly argues that a manufacturer's distribution agreements are subject to antitrust scrutiny. The FTC argues that under American Needle, Inc. v. Nat'l Football League, 130 S.Ct. 2201 (2010), Celgene and its distributors are separate economic entities, and thus their conduct should be analyzed under the rule of reason. While a single economic entity cannot be liable under Section 1 (and the distributors themselves have no independent interest in preventing sales to Mylan), the FTC argues the distributors need not be pursuing the same ends as Celgene in order for there to be an agreement in restraint of trade, and that Celgene's argument that its distributors function as its agents should not apply under these circumstances, where those distributors also distribute numerous other drugs.

Lastly, the FTC argues that the fact that Celgene has patents on the two drugs does not end the antitrust inquiry, as conduct that prevents competitors from appropriately challenging the patents (or bringing a product to market after a patent has expired) can still raise antitrust concerns.

The court has not yet issued a decision on the motion to dismiss, and it is not clear which (if any) of the arguments the FTC had made will be accepted. Nonetheless, the FTC's brief appears to be in line with its apparent policy of monitoring any restrictions that it believes may be restricting appropriate generic competition.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Related Topics
 
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions